Patents by Inventor Cassandra E. Callmann
Cassandra E. Callmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230181747Abstract: Aspects of the invention include a polymer comprising: a plurality of repeating units, each repeating unit comprising a polymer backbone group directly or indirectly covalently linked to one or two side chain moieties; wherein: each polymer backbone group is independently a ROMP-polymerized monomer; each one of the one or two side chain moieties independently comprises a peptide moiety or a non-peptide therapeutic moiety; wherein the polymer comprises a plurality of peptide moieties; each polymer backbone group is covalently attached to at least one other polymer backbone group; 100% of the ROMP-polymerized monomers are each individually attached to the one or two side chain moieties; and at least one side chain moiety of the polymer comprises a non-peptide therapeutic moiety, one polymer-terminating group comprises a non-peptide therapeutic moiety, and/or each of both polymer-terminating groups comprises a non-peptide therapeutic moiety.Type: ApplicationFiled: April 29, 2021Publication date: June 15, 2023Applicant: NORTHWESTERN UNIVERSITYInventors: Nathan C. GIANNESCHI, Matthew P. THOMPSON, Cassandra E. CALLMANN
-
Publication number: 20210047338Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.Type: ApplicationFiled: April 9, 2020Publication date: February 18, 2021Applicants: The Regents of the University of California, Vybyl Holdings, Inc.Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L.M. LeGuyader, Paul A. Bertin
-
Patent number: 10654864Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.Type: GrantFiled: April 4, 2018Date of Patent: May 19, 2020Assignees: The Regents of the University of California, Elevance Renewable Sciences, Inc.Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin
-
Publication number: 20200046846Abstract: The present disclosure generally provides nucleotide-based compounds useful for treating various diseases, including cancer. In some aspects, the disclosure provides oligonucleotides that are chemically modified to include an engineered fatty-acid residue, for example, to assist with improving the half-life of such compounds or assisting with cell penetration (e.g., penetration into tumor cells). In some aspects, the disclosure provides compositions that include such modified nucleotides and a protein, such as albumin or mimetics thereof. The disclosure provides various uses of the compounds and compositions.Type: ApplicationFiled: March 21, 2018Publication date: February 13, 2020Inventors: Alexander Roloff, Nathan C. Gianneschi, Cassandra E. Callmann, Matthew P, Thompson, Paul A. Bertin
-
Publication number: 20200046859Abstract: The present disclosure generally provides compounds useful as MRI contrast agents. In some aspects, the disclosure provides MRI contrast agents that are chemically modified to have one or more moieties that include hydrophobic portions. In some aspects, the disclosure provides compositions that include such modified MRI contrast agents and a protein, such as albumin or albumin mimetics. Further, the disclosure provides various uses of these compounds and compositions.Type: ApplicationFiled: April 25, 2018Publication date: February 13, 2020Inventors: Clare L.M. Leguyader, Nathan Gianneschi, Cassandra E. Callmann, Matthew P. Thompson, Treffly Ditri, Paul A. Bertin
-
Publication number: 20190381179Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.Type: ApplicationFiled: March 19, 2019Publication date: December 19, 2019Applicants: The Regents of the University of California, Vybyl Holdings, Inc.Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L.M. LeGuyader, Paul A. Bertin
-
Patent number: 10286079Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.Type: GrantFiled: March 22, 2017Date of Patent: May 14, 2019Assignees: The Regents of the University of California, Vybyl Holdings, Inc.Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin
-
Publication number: 20180222915Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.Type: ApplicationFiled: April 4, 2018Publication date: August 9, 2018Applicants: The Regents of the University of California, Vybyl Holdings, Inc.Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin
-
Patent number: 10023581Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.Type: GrantFiled: September 21, 2016Date of Patent: July 17, 2018Assignees: The Regents of the University of California, Vybyl Holdings, Inc.Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin
-
Publication number: 20180000951Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.Type: ApplicationFiled: March 22, 2017Publication date: January 4, 2018Applicants: The Regents of the University of California, Vybyl, Inc.Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin
-
Publication number: 20170080094Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.Type: ApplicationFiled: September 21, 2016Publication date: March 23, 2017Applicants: The Regents of the University of California, Vybyl, Inc.Inventors: Cassandra E. Callmann, Matthew P. Thompson, Nathan C. Gianneschi, Clare L. M. LeGuyader, Paul A. Bertin